Tempus AI Expands Rare Cancer Research and Validates ECG-AF Tool Amid Stock Market Gains

Tempus AI Inc. (NASDAQ: TEM) announced on June 25 2026 that it has entered a research collaboration with Angiosarcoma Aw...

Read story →